The aim of the study was to determine the cognitive impairment level influence in descriptive characteristics, comorbidities, complications, and pharmacological features of older adults with hip fracture.
Five hundred fifty-seven older adults with hip fracture were recruited and divided into cognitive impairment levels (severe/moderate, mild, no impairment). Descriptive characteristics, comorbidities, complications, and pharmacological data were collected.
Significant differences (p < .05, R2 = .012–.475) between cognitive impairment levels were shown. Shorter presurgery hospital length of stay and lower depression and Parkinson comorbidities; delirium complication; and antidepressants, antiparkinsonians, and neuroleptics use were shown for the no-impairment group. With regard to the cognitive impairment groups, lower presence of cardiopathy and hypertension; higher presence of dementia; antihypertensives, antiplatelets, and antidementia medication; infection/respiratory insufficiency complications; and lower constipation complications were shown.
Cognitive impairment levels may determine the characteristics, comorbidities, pharmacology, and complications of older adults with hip fracture.
Cognitive impairment level may impact rehabilitation nursing practice, education, and care coordination.
1 Ortogeiatric Unit, Complejo Asistencial Universitario de León (CAULE), León, Spain.
2 Nursing and Physical Therapy Department, Institute of Biomedicine (IBIOMED), Universidad de León, León, Spain.
3 Institute of Biomedicine (IBIOMED), University of León, León, Spain.
4 University of the Basque Country (UPV/EHU), Leioa, Spain.
Correspondence: César Calvo-Lobo, PhD, Nursing and Physical Therapy Department, Institute of Biomedicine (IBIOMED), Faculty of Health Sciences, University of León, Av. Astorga, s/n, 24401 Ponferrada, León, Spain. E-mail: email@example.com
The study was approved by the Clinical Research Ethics Committee of the León University (Spain; Code ÉTICA-ULE-004-2015). Informed written consent form was obtained from all participants before their inclusion in the research study. Furthermore, the Helsinki Declaration, Protection Data Organic Law (15/1999), and ethical standards in human experimentation were respected.